Vitality Biopharma announced additional preclinical efficacy results for the treatment of colitis.
Vitality Biopharma (OTCQB:VBIO) announced additional preclinical efficacy results for the treatment of colitis.
As quoted in the press release:
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can be targeted and limited to the gastrointestinal tract, thereby avoiding drug psychoactivity and unforeseen side effects. The Company has now successfully completed studies that demonstrate the efficacy of multiple different cannaboside drug formulations for treating preclinical models of colitis. Multiple different cannaboside drug formulations were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.
Based on these positive results, Vitality is advancing cannabosides into first-in-man clinical trials and later will conduct proof-of-concept clinical testing for treatment of inflammatory bowel disease (IBD).